Exenatide (Byetta) and insulin glargine (Lantus) achieve similar improvements in overall blood glucose control in people with type 2 diabetes who were not being controlled sufficiently on oral combination therapy.
In a 26-week multicenter randomized trial, physicians compared the effects of Byetta and Lantus on 551 patients with type 2 diabetes who had A1Cs ranging from 7% to 10% despite combination metformin and sulfonylurea therapy. Byetta was administered at dosages of 10 µg twice daily, or Lantus was administered once daily to maintain blood glucose at 100 mg/dl.
At week 26, both Byetta and Lantus reduced A1C levels by an average of 1.11%.
“[Byetta] reduced postprandial glucose excursions more than [Lantus],” write the researchers, “while [Lantus] reduced fasting glucose concentrations more than [Byetta].”
The researchers add that body weight decreased 5 pounds with Byetta and increased 4 pounds with Lantus.
Rates of hypoglycemia were similar, but nocturnal hypoglycemia occurred less frequently with the Byetta group. Gastrointestinal symptoms were more common in the Byetta group than in the Lantus group, including nausea (57.1 percent vs. 8.6 percent), vomiting (17.4 percent vs. 3.7% percent) and diarrhea (8.5 percent vs. 3.0 percent).
—Annals of Internal Medicine, October 18, 2005